- Generic name
- Mirabegron
- Strength
- 50 mg
- Dosage form
- Er Tablet
- Manufactured by
- Opsonin Pharma Limited
Megron 50 Er Tablet
About Megron 50 Er Tablet
Megron 50 comes as a er tablet with 50 mg of Mirabegron, from Opsonin Pharma Limited. Mirabegron is indicated for the symptomatic treatment of urgency, increased micturition frequency and urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome.
There are 10 brands of Mirabegron listed in Bangladesh. The lowest listed price is Betmira ER 25 mg Tablet (Extended Release) at ৳ 30.00 per unit.
What is Megron 50 Er Tablet?
Megron 50 is a er tablet from Opsonin Pharma Limited, with the generic name Mirabegron. Mirabegron is indicated for the symptomatic treatment of urgency, increased micturition frequency and urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome. The doctor decides the dose and course.
Uses of Megron 50
Mirabegron is indicated for the symptomatic treatment of urgency, increased micturition frequency and urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome. Your doctor will decide if it is suitable for you.
How to use Megron 50
Swallow the er tablet with water. Megron 50 is taken by mouth. Take Megron 50 as your doctor tells you. Do not change the dose or stop early without asking your doctor. If you miss a dose, ask your doctor or pharmacist what to do.
Side effects of Megron 50
Contact your doctor if you notice anything unusual after taking it. Tell your doctor if any side effect bothers you or does not go away.
Safety and precautions
Hypertension : Mirabegron can increase blood pressure. Mirabegron is not recommended during pregnancy and in women is planning to be pregnant. Mirabegron is excreted in the milk of rodents and therefore is predicted to be present in human milk. Keep out of reach of children.
Frequently asked questions
Why is Megron 50 prescribed?
Mirabegron is indicated for the symptomatic treatment of urgency, increased micturition frequency and urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome. Your doctor will decide if it is suitable for you.
How should I take Megron 50?
Swallow the er tablet with water. Megron 50 is taken by mouth.
What are the side effects of Megron 50?
Contact your doctor if you notice anything unusual after taking it. Tell your doctor if any side effect bothers you or does not go away.
Is Megron 50 safe for everyone?
Hypertension : Mirabegron can increase blood pressure. Mirabegron is not recommended during pregnancy and in women is planning to be pregnant.
Indications
Pharmacology
Dosage & Administration
Renal or hepatic impairment:
- Patients with severe renal impairment (ClCr 15 to 29 mL/min or eGFR 15 to 29 mL/min/1.73 m2) or moderate hepatic impairment (Child-Pugh Class B), the daily dose of Mirabegron should not exceed 25 mg tablet once daily.
- Mirabegron has not been studied in patients with end stage renal disease (GFR <15 mL/min/1.73 m2 or patients requiring haemodialysis) or severe hepatic impairment (Child Pugh Class C) and it is therefore not recommended for use in these patient populations.
Paediatric population: The safety and efficacy of Mirabegron in children below 18 years of age have not yet been established.
Interaction
Effect of enzyme inducers: Substances that are inducers of CYP3A or P-gp decrease the plasma concentrations of Mirabegron. No dose adjustment is needed for Mirabegron when administered with therapeutic doses of rifampicin or other CYP3A or P-gp inducers.
Effect of Mirabegron on CYP2D6 substrates: In healthy volunteers, the inhibitory potency of Mirabegron towards CYP2D6 is moderate and the CYP2D6 activity recovers within 15 days after discontinuation of Mirabegron. Multiple once daily dosing of Mirabegron IR resulted in a 90% increase in Cmax and a 229% increase in AUC of a single dose of metoprolol. Multiple once daily dosing of Mirabegron resulted in a 79% increase in Cmax and a 241% increase in AUC of a single dose of desipramine. Caution is advised if Mirabegron is co-administered with medicinal products with a narrow therapeutic index and significantly metabolised by CYP2D6, such as thioridazine, Type 1 C antiarrhythmics (e.g., flecainide, propafenone) and tricyclic antidepressants (e.g., imipramine, desipramine). Caution is also advised if Mirabegron is co-administered with CYP2D6 substrates that are individually dose titrated.
Effect of Mirabegron on transporters: Mirabegron is a weak inhibitor of P-gp. Mirabegron increased Cmax and AUC by 29% and 27%, respectively, of the P-gp substrate digoxin in healthy volunteers. For patients who are initiating a combination of Mirabegron and digoxin, the lowest dose for digoxin should be prescribed initially. Serum digoxin concentrations should be monitored and used for titration of the digoxin dose to obtain the desired clinical effect.
Other interactions: No clinically relevant interactions have been observed when Mirabegron was co-administered with therapeutic doses of solifenacin, tamsulosin, warfarin, metformin or a combined oral contraceptive medicinal product containing ethinylestradiol and levonorgestrel. Dose-adjustment is not recommended.
Contraindications
Side Effects
Pregnancy & Lactation
Precautions & Warnings
Hepatic impairment: Mirabegron has not been studied in patients with severe hepatic impairment (Child-Pugh Class C) and, therefore, it is not recommended for use in this patient population. Mirabegron is not recommended for use in patients with moderate hepatic impairment (Child-Pugh Class B) concomitantly receiving strong CYP3A inhibitors.
Hypertension: Mirabegron can increase blood pressure. Blood pressure should be measured at baseline and periodically during treatment with Mirabegron, especially in hypertensive patients. Data are limited in patients with stage 2 hypertension (systolic blood pressure 160 mm Hg or diastolic blood pressure 100 mm Hg).
Patients with congenital or acquired QT prolongation: Caution should be exercised when administering Mirabegron in patients with congenital or acquired QT prolongation.
Patients with bladder outlet obstruction and patients taking antimuscarinics medications for OAB: A controlled clinical safety study in patients with bladder outlet obstruction (BOO) did not demonstrate increased urinary retention in patients treated with Mirabegron; however, Mirabegron should be administered with caution to patients with clinically significant bladder outlet obstruction. Mirabegron should also be administered with caution to patients taking antimuscarinic medications for the treatment of OAB.
Overdose Effects
Storage Conditions
Alternative brands of Mirabegron
Other brands with the same generic name, cheapest first.
Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.